AstraZeneca plc has announced several recent contract and collaboration updates. The company completed an agreement with AbelZeta, granting AstraZeneca the sole global rights to develop, manufacture, and commercialise C-CAR031. AbelZeta will receive up to $630 million, including an upfront payment and milestone payments for the GPC3 program in China. Additionally, AstraZeneca entered a strategic collaboration with CSPC Pharmaceuticals, securing exclusive global rights outside China to CSPC’s weight management portfolio, which includes SYH2082 and three preclinical programs. CSPC will receive an upfront payment of $1.2 billion and may earn up to $3.5 billion in development and regulatory milestones, along with further commercial and sales milestones and tiered royalties. AstraZeneca also signed an agreement with Jacobio Pharma for the development and commercialisation of JAB-23E73 outside China. Jacobio will receive a $100 million upfront payment and is eligible for up to $1.9 billion in milestone payments, as well as tiered royalties on net sales outside China. In addition, AstraZeneca paid Bristol-Myers Squibb Company $170 million to eliminate royalties payable on Saphnelo sales outside the US; royalties on US sales will continue at a mid-teens percentage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209280778) on February 10, 2026, and is solely responsible for the information contained therein.